Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Statistical Sampling

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    58 result(s) found for: Statistical Sampling. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2011-002955-33 Sponsor Protocol Number: 027SC10363 Start Date*: 2012-02-16
    Sponsor Name:Aziende Chimiche Riunite Angelini Francesco S.p.A
    Full Title: Clinical and microbiological assessment of prulifloxacin in patients with Acute Bacterial Rhinosinusitis (ABRS)
    Medical condition: Male or female adults with ABRS, defined as the presence of 2 (including at least one between nasal blockage/congestion/ obstruction or nasal discharge) or more of the following signs and symptoms:...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-003259-39 Sponsor Protocol Number: NeuroClin02 Start Date*: 2014-03-28
    Sponsor Name:Neurochlore
    Full Title: A Phase II dose ranging study of Bumetanide solution in children and adolescents with autism spectrum disorders.
    Medical condition: Diseases and Related Health Problems, tenth revision (ICD-10) and with a Childhood Autism Rating Scale (CARS) score > 34.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002973-13 Sponsor Protocol Number: LOCAL/2013/JYL-01 Start Date*: 2015-02-25
    Sponsor Name:CHU de NIMES
    Full Title: Sampling Antibiotics in Renal Replacement Therapy: the AZUREA contribution
    Medical condition: The study population concerns patients in participating Intensive care unit simultaneously requiring Renal Replacement Therapy and intravenous antibiotic therapy (Piperacillin-Tazobactam, Meropenem...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002366-40 Sponsor Protocol Number: 13.0095 Start Date*: 2013-07-19
    Sponsor Name:St George’s, University of London
    Full Title: Neonatal and Paediatric Pharmacokinetics of Antimicrobials study
    Medical condition: The study is not restricted to any specific condition. The study population will include children (aged under 16 years) admitted to hospital and routinely prescribed one of the study penicillins ac...
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-001772-55 Sponsor Protocol Number: XM02-ONC-201 Start Date*: 2015-01-26
    Sponsor Name:TEVA Pharmaceutical Industries Ltd
    Full Title: A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 μg/kg tbo-filgrastim...
    Medical condition: Chemotherapy induced Neutropenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004851 10029355 Neutropenias HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) PL (Completed) RO (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2009-012876-29 Sponsor Protocol Number: 10762 Start Date*: 2009-07-07
    Sponsor Name:University Hospitals Leicester
    Full Title: A prospective study to assess emergence and transmissibility of drug resistance to neuraminidase inhibitor following treatment of children and adults with acute pandemic influenza
    Medical condition: Influenza
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006579-19 Sponsor Protocol Number: MP-EG-002 Start Date*: 2007-04-19
    Sponsor Name:Egalet a/s
    Full Title: A double-blind, randomized, 2-way cross-over, phase II, efficacy trial in cancer patients to assess the overall efficacy, patient preference, morphine related side effect profile and safety of the ...
    Medical condition: cancer patients
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058019 Cancer pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003394-15 Sponsor Protocol Number: VP-VEC-162-4201 Start Date*: 2016-06-28
    Sponsor Name:Vanda Pharmaceuitcals Inc.
    Full Title: OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY OF TASIMELTEON IN TOTALLY BLIND CHILDREN AND ADOLESCENTS WITH NON-24-HOUR SLEEP- WAKE DISORDER
    Medical condition: This study will be an open-label, single dose, non-controlled trial to evaluate the pharmacokinetics and safety of tasimelteon in children who are 3 years to less than 18 years of age, totally blin...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10040984 Sleep disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000412-28 Sponsor Protocol Number: P2020_284 Start Date*: 2021-02-17
    Sponsor Name:Hopital Erasme, Université Libre de Bruxelles
    Full Title: COVID-19: Sars-Cov2 vaccination in kidney transplant patient: a phase IV study of the immunogenicity and its determinants
    Medical condition: Kidney transplant patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000461-33 Sponsor Protocol Number: P2020_312 Start Date*: 2021-02-17
    Sponsor Name:Hopital Erasme, Université Libre de Bruxelles
    Full Title: Covid-19: Sars-Cov2 vaccination in hemodialysis patient: a phase IV study of the immunogenicity and its determinants
    Medical condition: Chronic hemodialysis patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000821-31 Sponsor Protocol Number: 307969 Start Date*: 2004-11-16
    Sponsor Name:Schering AG
    Full Title: Multi-center, open, randomized, parallel group comparison of cycle control for seven cycles and endometrial safety in a subgroup for thirteen cycles of contraceptive patch SH P00331F (0.9 mg ethiny...
    Medical condition: Contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002221-29 Sponsor Protocol Number: VIT-2763-THAL-201 Start Date*: 2020-02-25
    Sponsor Name:Vifor (International) Inc.
    Full Title: A Phase 2a, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Study on Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Doses of...
    Medical condition: Non-transfusion Dependent Beta-thalassaemia.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10074355 Non-transfusion dependent thalassaemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006099-38 Sponsor Protocol Number: P-piller102 Start Date*: 2012-08-06
    Sponsor Name:Karolinska University Hospital
    Full Title: Effects of an antiandrogenic oral contraceptive on eating behaviour in women with bulimia – A randomized double blinded, placebo controlled study.
    Medical condition: Bulimia nervosa is an eating disorder with a prevalence of about 2% in young women (Fairburn and Beglin, 1990). It is characterized by frequent binge eating episodes and the regular use of inapprop...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001283-73 Sponsor Protocol Number: 109493 Start Date*: 2007-08-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable ...
    Medical condition: Adjuvant therapy in patients with MAGE-A3-positive Non-Small Cell Lung Cancer (NSCLC) and who have had complete surgical resection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029517 Non-small cell lung cancer stage I PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) IE (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) SI (Prematurely Ended) FR (Completed) SE (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) AT (Completed) NL (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) EE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001599-46 Sponsor Protocol Number: F1J-MC-HMGI Start Date*: 2017-05-09
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
    Medical condition: Generalized Anxiety Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-004530-14 Sponsor Protocol Number: 1199-0337 Start Date*: 2019-10-15
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with nin...
    Medical condition: Interstitial Lung Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066393 Respiratory bronchiolitis-associated interstitial lung disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) PT (Completed) FI (Completed) NO (Completed) DK (Completed) FR (Completed) CZ (Completed) PL (Completed) GR (Completed) HU (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed) BE (Ongoing) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-022647-38 Sponsor Protocol Number: P06107 Start Date*: 2011-11-16
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: Efficacy and Safety of 3-Week Fixed-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated with Bipolar I Disorder (Protocol No. P06107)
    Medical condition: Acute Manic or Mixed Episodes Associated with Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10068455 Bipolar I disorder, hypomanic LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001598-18 Sponsor Protocol Number: F1J‐MC‐HMCL Start Date*: 2017-05-09
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-005537-32 Sponsor Protocol Number: D419QC00007 Start Date*: 2021-07-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination with Platinum and Etoposide for the First Line Treatment of Patients with Extensive-stage Small Cell Lung Ca...
    Medical condition: Extensive-stage Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) BG (Ongoing) IT (Ongoing) CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003184-62 Sponsor Protocol Number: J1369 Start Date*: 2014-04-23
    Sponsor Name:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Full Title: A phase I study of SGI-110 combined with irinotecan followed by a randomized phase II study of SGI-110 combined with irinotecan versus regorafenib in previously treated metastatic colorectal cancer...
    Medical condition: Previously treated metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:57:21 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA